Literature DB >> 9848651

Enhancer elements activate the weak 3' splice site of alpha-tropomyosin exon 2.

B T Dye1, M Buvoli, S A Mayer, C H Lin, J G Patton.   

Abstract

We have identified four purine-rich sequences that act as splicing enhancer elements to activate the weak 3' splice site of alpha-tropomyosin exon 2. These elements also activate the splicing of heterologous substrates containing weak 3' splice sites or mutated 5' splice sites. However, they are unique in that they can activate splicing whether they are placed in an upstream or downstream exon, and the two central elements can function regardless of their position relative to one another. The presence of excess RNAs containing these enhancers could effectively inhibit in vitro pre-mRNA splicing reactions in a substrate-dependent manner and, at lower concentrations of competitor RNA, the addition of SR proteins could relieve the inhibition. However, when extracts were depleted by incubation with biotinylated exon 2 RNAs followed by passage over streptavidin agarose, SR proteins were not sufficient to restore splicing. Instead, both SR proteins and fractions containing a 110-kD protein were necessary to rescue splicing. Using gel mobility shift assays, we show that formation of stable enhancer-specific complexes on alpha-tropomyosin exon 2 requires the presence of both SR proteins and the 110-kD protein. By analogy to the doublesex exon enhancer elements in Drosophila, our results suggest that assembly of mammalian exon enhancer complexes requires both SR and non-SR proteins to activate selection of weak splice sites.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9848651      PMCID: PMC1369723          DOI: 10.1017/s1355838298980360

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  60 in total

1.  A conserved double-stranded RNA-binding domain.

Authors:  D St Johnston; N H Brown; J G Gall; M Jantsch
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

2.  Site-specific modification of pre-mRNA: the 2'-hydroxyl groups at the splice sites.

Authors:  M J Moore; P A Sharp
Journal:  Science       Date:  1992-05-15       Impact factor: 47.728

3.  SR proteins: a conserved family of pre-mRNA splicing factors.

Authors:  A M Zahler; W S Lane; J A Stolk; M B Roth
Journal:  Genes Dev       Date:  1992-05       Impact factor: 11.361

4.  Sex-specific splicing and polyadenylation of dsx pre-mRNA requires a sequence that binds specifically to tra-2 protein in vitro.

Authors:  M L Hedley; T Maniatis
Journal:  Cell       Date:  1991-05-17       Impact factor: 41.582

Review 5.  SR proteins and splicing control.

Authors:  J L Manley; R Tacke
Journal:  Genes Dev       Date:  1996-07-01       Impact factor: 11.361

6.  Positive control of pre-mRNA splicing in vitro.

Authors:  M Tian; T Maniatis
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

7.  Regulation of doublesex pre-mRNA processing occurs by 3'-splice site activation.

Authors:  L C Ryner; B S Baker
Journal:  Genes Dev       Date:  1991-11       Impact factor: 11.361

8.  Development and characterization of a cloned rat pulmonary arterial smooth muscle cell line that maintains differentiated properties through multiple subcultures.

Authors:  A Rothman; T J Kulik; M B Taubman; B C Berk; C W Smith; B Nadal-Ginard
Journal:  Circulation       Date:  1992-12       Impact factor: 29.690

9.  The 35-kDa mammalian splicing factor SC35 mediates specific interactions between U1 and U2 small nuclear ribonucleoprotein particles at the 3' splice site.

Authors:  X D Fu; T Maniatis
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-01       Impact factor: 11.205

10.  The role of exon sequences in splice site selection.

Authors:  A Watakabe; K Tanaka; Y Shimura
Journal:  Genes Dev       Date:  1993-03       Impact factor: 11.361

View more
  16 in total

1.  Identification of a bidirectional splicing enhancer: differential involvement of SR proteins in 5' or 3' splice site activation.

Authors:  C F Bourgeois; M Popielarz; G Hildwein; J Stevenin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Identification and characterization of a novel serine-arginine-rich splicing regulatory protein.

Authors:  D C Barnard; J G Patton
Journal:  Mol Cell Biol       Date:  2000-05       Impact factor: 4.272

Review 3.  RNA-protein interactions that regulate pre-mRNA splicing.

Authors:  Ravinder Singh
Journal:  Gene Expr       Date:  2002

4.  Roles of hnRNP A1, SR proteins, and p68 helicase in c-H-ras alternative splicing regulation.

Authors:  Sònia Guil; Renata Gattoni; Montserrat Carrascal; Joaquín Abián; James Stévenin; Montse Bach-Elias
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

5.  PSF and p54nrb bind a conserved stem in U5 snRNA.

Authors:  Rui Peng; Billy T Dye; Ismael Pérez; Daron C Barnard; Amanda B Thompson; James G Patton
Journal:  RNA       Date:  2002-10       Impact factor: 4.942

Review 6.  Regulation of alternative RNA splicing by exon definition and exon sequences in viral and mammalian gene expression.

Authors:  Zhi-Ming Zheng
Journal:  J Biomed Sci       Date:  2004 May-Jun       Impact factor: 8.410

7.  An apparent pseudo-exon acts both as an alternative exon that leads to nonsense-mediated decay and as a zero-length exon.

Authors:  Sushma-Nagaraja Grellscheid; Christopher W J Smith
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

8.  Differing patterns of selection in alternative and constitutive splice sites.

Authors:  Kavita Garg; Phil Green
Journal:  Genome Res       Date:  2007-06-07       Impact factor: 9.043

9.  A splicing silencer that regulates smooth muscle specific alternative splicing is active in multiple cell types.

Authors:  Natalia Gromak; Christopher W J Smith
Journal:  Nucleic Acids Res       Date:  2002-08-15       Impact factor: 16.971

10.  The PTB interacting protein raver1 regulates alpha-tropomyosin alternative splicing.

Authors:  Natalia Gromak; Alexis Rideau; Justine Southby; A D J Scadden; Clare Gooding; Stefan Hüttelmaier; Robert H Singer; Christopher W J Smith
Journal:  EMBO J       Date:  2003-12-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.